Arthex Biotech S.L. is a biotechnology company based in Paterna, Spain, that specializes in the development of antisense RNA therapies for genetic diseases. Founded in 2019 as a spin-off from the University of Valencia, the company focuses on addressing unmet medical needs through innovative treatments targeting microRNAs, which are implicated in various disorders, including neuromuscular diseases. With a team experienced in drug discovery and strong support from leading scientific and clinical advisors, Arthex Biotech aims to provide effective therapies for patients suffering from rare and challenging conditions.
Norbite is a biotech research firm focused on converting plastic waste into sustainable products through an innovative insect-based biorefinery. The company's technology integrates biorefinery and vertical farming methods to process plastic waste, yielding larvae that are bio-refined into proteins suitable for food and feed applications. By offering sustainable solutions, Norbite aims to contribute positively to environmental efforts while providing clients with valuable products and services.
TILT Biotherapeutics Ltd is a preclinical stage biotechnology company based in Helsinki, Finland, focused on developing genetically modified oncolytic viruses to improve cancer treatments. Established in 2013, the company aims to enhance tumor T-cell therapies through its patented technology, which utilizes oncolytic viruses to modify the tumor microenvironment and counteract its immune-suppressive properties. TILT Biotherapeutics is advancing several product candidates, including TILT-123, TILT-234, and TILT-321, and plans to translate its innovative approach into clinical trials. The technology is designed to bolster the effectiveness of tumor-infiltrating lymphocyte (TIL) therapies, chimeric antigen receptor (CAR-T) therapies, and checkpoint inhibitors, potentially achieving outcomes in solid tumors similar to those seen in hematological cancers.
TILT Biotherapeutics Ltd is a preclinical stage biotechnology company based in Helsinki, Finland, focused on developing genetically modified oncolytic viruses to improve cancer treatments. Established in 2013, the company aims to enhance tumor T-cell therapies through its patented technology, which utilizes oncolytic viruses to modify the tumor microenvironment and counteract its immune-suppressive properties. TILT Biotherapeutics is advancing several product candidates, including TILT-123, TILT-234, and TILT-321, and plans to translate its innovative approach into clinical trials. The technology is designed to bolster the effectiveness of tumor-infiltrating lymphocyte (TIL) therapies, chimeric antigen receptor (CAR-T) therapies, and checkpoint inhibitors, potentially achieving outcomes in solid tumors similar to those seen in hematological cancers.
Blue Planet Ecosystems Incorporated, founded in 2018 and based in San Francisco, California, specializes in the development and operation of modular closed loop photo protein reactors aimed at sustainable food production in challenging environments. The company utilizes innovative technology to produce high-quality, pollutant-free fish, leveraging selected strains of green microalgae and advanced algorithms. By converting CO2 and sunlight into essential nutrients such as sugars, amino acids, and fatty acids, their systems create a sustainable food source for zooplankton and fish. This approach enables farmers and agricultural businesses to diversify their methods and adapt to the impacts of climate change and urbanization.
Beeodiversity is a company with a societal positif impact. Beeodiversity assists companies and local authorities to set up strategies and develop environmental projects generating added value for the environment, the partner and its stakeholders. It combines a scientific expertise, innovative tools based on nature and environmental coaching techniques.
Protinhi Therapeutics is a preclinical stage biotechnology company focused on developing antiviral drugs to combat various viral threats, including dengue, Zika, and COVID-19. The company's innovative approach utilizes proprietary technology and compounds that target viral diseases through protease inhibition. This mechanism disrupts the viruses' ability to replicate, providing healthcare providers with a means to effectively control the spread of these infections. By concentrating on significant public health challenges, Protinhi Therapeutics aims to contribute to global efforts in managing and mitigating viral outbreaks.
Developer of autonomous greenhouse food production and indoor agriculture robots designed to automate tasks for food production in greenhouse horticulture sector industries. The company specializes in developing harvest and crop-handling robots and artificial intelligence-robotic harvester systems for indoor farming and eliminating factors like climate change and food security pressure, enabling farmers with a controlled climate and protection from the changes outside to get better yields with less land usage.
Ovagen is a biotechnology company that has developed the process of producing germ free (GF) chicken eggs and GF birds in commercial quantities for use primarily in the pharmaceutical industry. Ovagen can also provide a Contract Research Service and has extensive expertise in SPF poultry & rodent housing & husbandry, in specific poultry & rodent research technologies to GMP standards and in avian transgenics.
Onward is developing an Implantable Neuro-stimulation System (INS) with real-time motion feedback and uses training tools to rehabilitate patients suffering from neurological disorders such as spinal cord injury (SCI).
Limula Biotech is a Swiss company specializing in the design and development of an automated system for manufacturing cell and gene therapies. The company has created a patented platform that enables the distributed production of genetically engineered cells directly at the patient's bedside, utilizing a patient's white blood cell sample. This fully closed bioreactor system minimizes human intervention during the manufacturing process while maintaining control over cell culture parameters. By facilitating on-site production in hospitals, Limula's technology aims to enhance the safety, accessibility, and efficiency of personalized gene therapies, ultimately reducing time, costs, and logistical challenges. Founded in 2018 and based in Lausanne, Switzerland, Limula Biotech is committed to revolutionizing the delivery of ex vivo gene-engineered cell therapies.
Aviwell is focused on creating healthy, natural, and sustainable solutions aimed at enhancing animal health and growth, thereby contributing to global nourishment. The company operates a microbiota-based discovery platform that leverages artificial intelligence and machine learning to bridge digital and life sciences. By developing innovative food products, Aviwell seeks to provide valuable insights into animal health, growth, and performance, ultimately supporting the agri-food industry in its efforts to sustainably meet the needs of a growing population.
Qubit Pharmaceuticals, incorporated in 2020 and based in Paris, France, develops innovative technology aimed at enhancing pharmaceutical drug discovery. The company offers a drug discovery simulation platform that reduces the cost and duration of preclinical drug development. Utilizing proprietary force field models and molecular dynamics calculations, Qubit's platform conducts virtual screening and visualization to identify promising drug candidates. This approach leverages quantum physics to support biopharmaceutical companies in accelerating their research and development efforts.
Neurosoft Bioelectronics specializes in the development of soft implantable electrodes designed to interface with the nervous system for diagnosing and treating neurological disorders. Based in Geneva, Switzerland, the company has created next-generation electrodes that are compliant and conformable, addressing the limitations of existing stiff devices. Their flagship product, SOFT ECoG, is a subdural electrode that records from and stimulates the brain's surface, enhancing recording quality and minimizing MRI artifacts. Neurosoft's technology promotes long-term bio-integration, adapting to both static and dynamic mechanics of neural tissue, which can improve therapeutic outcomes for patients and expand the applications of neural interfaces in clinical settings.
DePoly is a spin off out of the LSMO lab at EPFL- Valais that has developed a novel technology allowing for the chemical recycling of PET plastic back to its main two components ethylene glycol (EG) and terephthalic acid (TPA). Our approach turns low valued materials (PET waste) into high-valued chemicals like TPA creating a circular economy. We expect this process to generate revenue from chemically recycling PET to TPA/EG, which can be sold back to industry to make new virgin PET plastic and allowing for a sustainable source of TPA and EG on the market.
Perha Pharmaceuticals is a biotechnology company dedicated to the research and development of innovative therapies aimed at addressing hearing loss and cognitive disorders. The company focuses on preventing cisplatin-induced hearing loss and developing treatments for cognitive conditions related to Down syndrome and Alzheimer's disease. Perha Pharmaceuticals leverages natural marine substances in its research, with chemists and biologists optimizing molecules derived from marine organisms to create effective kinase inhibitors. This approach underscores the company's commitment to advancing medical treatments and improving patient care in areas of significant unmet need.
Scipio Bioscience is a biotechnology company based in Paris, France, founded in 2017. The company specializes in manufacturing benchtop kits that serve as a sample preparation solution for single-cell studies. These kits are designed for use in sequencing applications within both clinical and basic research, focusing particularly on transcriptomics. By enabling single-cell barcoding in a test tube format, Scipio Bioscience's products facilitate advanced research in single-cell analysis, supporting laboratories in their scientific endeavors.
Ovagen is a biotechnology company that has developed the process of producing germ free (GF) chicken eggs and GF birds in commercial quantities for use primarily in the pharmaceutical industry. Ovagen can also provide a Contract Research Service and has extensive expertise in SPF poultry & rodent housing & husbandry, in specific poultry & rodent research technologies to GMP standards and in avian transgenics.
Genetika+ is developing a personalized medical testing tool to better treat depression by helping physicians find the best drug therapy for their patients. The Genetika+ test uses innovative technology to predict the best drug treatment for each patient, enabling faster treatment, fewer side effects, and lower dosing.
Novolyze, SAS is a French company that specializes in food safety solutions for the global food processing industry. Established in 2012 and headquartered in Daix, with an additional office in Cambridge, Massachusetts, Novolyze provides a comprehensive range of equipment, including steam pasteurizers, sterilizers, dryers, roasters, extruders, and ovens. The company is also known for its innovative surrogate microorganisms technology, which allows food manufacturers to test the effectiveness of microbial kill steps under real-life conditions. In addition to its equipment offerings, Novolyze provides services in pasteurization, regulatory compliance, and process validation, as well as food microbiology research to a diverse clientele that includes large corporations, small and medium enterprises, public and private research laboratories, and food processing associations. With a strong emphasis on enhancing food safety and quality, Novolyze employs a team of experts, including food microbiologists and process engineers, and operates state-of-the-art facilities in a pharmaceutical-grade environment for research and development.
Core Biogenesis is a biotechnology company building next-generation recombinant protein production technologies. The company uses proprietary gene editing and plant biotechnology to drastically reduce the cost of making growth factors. The growth factors are molecules used in the clean meat and cell therapy industries.
CH-Bioforce provides a revolutionary technology for converting all biomass components into high-value material streams - dissolving pulp, polymeric hemicellulose, and sulphur-free lignin. These valuable biomaterials can replace fossil and food-based raw materials in multiple industries, such as textiles and packaging applications.
TILT Biotherapeutics Ltd is a preclinical stage biotechnology company based in Helsinki, Finland, focused on developing genetically modified oncolytic viruses to improve cancer treatments. Established in 2013, the company aims to enhance tumor T-cell therapies through its patented technology, which utilizes oncolytic viruses to modify the tumor microenvironment and counteract its immune-suppressive properties. TILT Biotherapeutics is advancing several product candidates, including TILT-123, TILT-234, and TILT-321, and plans to translate its innovative approach into clinical trials. The technology is designed to bolster the effectiveness of tumor-infiltrating lymphocyte (TIL) therapies, chimeric antigen receptor (CAR-T) therapies, and checkpoint inhibitors, potentially achieving outcomes in solid tumors similar to those seen in hematological cancers.
Nagi Bioscience SA, based in Lausanne, Switzerland, specializes in the development and manufacturing of an innovative automated testing device that utilizes Caenorhabditis elegans, a type of microscopic worm, for the assessment of substances in pharmaceutical, chemical, and cosmetic industries. This technology, known as "Organism-on-Chip," integrates in vivo testing with a fully automated in vitro platform for handling, culturing, and analyzing these organisms. Nagi Bioscience's solutions facilitate toxicity testing, drug discovery, and anthelmintic testing, allowing clients to gain insights into the complete biological responses that can only be observed at the organism level. This approach aims to transform traditional methods of evaluating the toxic or beneficial effects of various substances.
Bloom Biorenewables Ltd is a company focused on developing innovative technology to convert wood and agricultural waste into renewable materials that can replace petroleum-based products. Incorporated in 2019 and based in Marly, Switzerland, the company aims to provide sustainable alternatives for various industries, including chemicals, fragrances, plastics, and textiles. By employing a biomass deconstruction technology platform, Bloom Biorenewables offers a cost-effective method to extract bio-based molecules from plant materials. This approach not only helps customers reduce their reliance on fossil fuels but also contributes to efforts in mitigating climate change by lowering carbon footprints and supporting the transition to a circular economy.
Betalin Therapeutics is a privately-held company focused on developing a cell therapy solution for insulin-dependent diabetes through its Engineered Micro-Pancreas (EMP) technology. The EMP combines harvested pancreatic islets, known as Islets of Langerhans, with a proprietary biological micro-environment designed to support these cells. After achieving promising in-vitro results and preliminary in-vivo outcomes, the company is working to further optimize its therapy in animal models. Betalin Therapeutics aims to complete the submission of its Investigational New Drug application to the FDA and advance to clinical trials, with the goal of providing an alternative to traditional insulin therapy and eliminating the need for insulin injections and glucose testing in diabetes patients.
Spartha Medical is a medical technology company focused on developing eco-friendly, invisible coatings designed for medical devices and consumer products to mitigate microbial and inflammatory risks. Utilizing natural biopolymers, the company’s innovative coatings possess antibacterial, antiviral, and anti-inflammatory properties, providing an effective solution for infection control. The technology relies on a patented method of supramolecular assembly, enabling precise control over the properties of the coatings based on specific applications. This approach allows for the creation of multifunctional and easy-to-apply surface treatments that help healthcare institutions maintain disease-free environments on medical devices.
Amadix is focused on developing and commercializing innovative cancer diagnostic technologies that address unmet medical needs in oncology. The company's flagship product, Colofast, is a non-invasive screening signature for colorectal cancer and advanced adenoma diagnosis, aimed at reducing the high mortality rate associated with colon cancer. Amadix's approach emphasizes early detection, allowing for timely treatment while avoiding the complications of invasive procedures like tumor biopsies. The team comprises industry veterans with extensive expertise in oncology diagnostics, the pharmaceutical industry, and biotechnology, supported by independent board members who provide strategic guidance in commercialization and business development, particularly in Europe and the United States. Amadix's products undergo rigorous analytical validation and clinical studies before being introduced to the global market.
BOYDSense specializes in developing non-invasive and affordable tools for measuring critical biomarkers via the exhaled breath. The company provides breath-based metabolomics focuses on the capture, identification, and quantification of volatile organic compound (VOC) biomarker patterns in human breath and using it to diagnose and monitor chronic diseases. It was founded in 2015 and headquartered in South San Francisco, California.
VBL Therapeutics is a clinical-stage biotechnology company dedicated to developing innovative treatments for cancer and immune-inflammatory diseases. Founded to address significant unmet medical needs, the company focuses on creating therapies that surpass the limitations of currently available options. Its clinical pipeline is built on two proprietary platform technologies that utilize the body’s natural physiological and genetic regulatory mechanisms. The lead candidate, VB-111, is a gene-based biologic targeting solid tumors, specifically for recurrent glioblastoma, an aggressive brain cancer. In addition to its oncology efforts, VBL is also advancing a program aimed at anti-inflammatory diseases, leveraging its Lecinoxoid platform technology.
VBL Therapeutics is a clinical-stage biotechnology company dedicated to developing innovative treatments for cancer and immune-inflammatory diseases. Founded to address significant unmet medical needs, the company focuses on creating therapies that surpass the limitations of currently available options. Its clinical pipeline is built on two proprietary platform technologies that utilize the body’s natural physiological and genetic regulatory mechanisms. The lead candidate, VB-111, is a gene-based biologic targeting solid tumors, specifically for recurrent glioblastoma, an aggressive brain cancer. In addition to its oncology efforts, VBL is also advancing a program aimed at anti-inflammatory diseases, leveraging its Lecinoxoid platform technology.
Perha Pharmaceuticals is a biotechnology company dedicated to the research and development of innovative therapies aimed at addressing hearing loss and cognitive disorders. The company focuses on preventing cisplatin-induced hearing loss and developing treatments for cognitive conditions related to Down syndrome and Alzheimer's disease. Perha Pharmaceuticals leverages natural marine substances in its research, with chemists and biologists optimizing molecules derived from marine organisms to create effective kinase inhibitors. This approach underscores the company's commitment to advancing medical treatments and improving patient care in areas of significant unmet need.
Criam is a biotechnology company based in Braga, Portugal, founded in 2015, that focuses on developing medical devices for blood type analysis and disease detection. The company's flagship product, also named Criam, enables rapid and affordable blood test analysis, allowing users to receive immediate information about their health. This medical device can detect various diseases, including HIV, Brucella, tick fever, syphilis, mononucleosis, and meningitis. By positioning itself in the Point-of-Care diagnostic segment, Criam aims to empower individuals with timely health information and contribute to the global monitoring and control of diseases.
EVerZom is a nanomedicine biotech company providing a large scale of GMP manufacturing platform of extracellular vesicles. They develop a bioproduction platform to produce extracellular vesicles at a commercial scale in a GMP compliant way for pharmaceutical companies with applications in regenerative medicine and drug delivery. Extracellular vesicles that encompass exosomes, microvesicles, and apoptotic bodies are the tools used by cells to communicate with each other. EVerZom was founded in 2019 and is headquartered in Paris, Ile-de-France, France.
Provider of advanced materials intended to produce bioplastic film, plastics, and coatings from agriculture residues. The company's technology uses food production residues to produce materials that are compostable under natural composting conditions and provides a marketable product from agricultural residues such as starch or brewery residues as a raw material for home compostable, harmless for the environment and humans, enabling the society to get rid of the plastic materials that lead to serious environmental, marine pollution and lower carbon emissions.
Provider of advanced materials intended to produce bioplastic film, plastics, and coatings from agriculture residues. The company's technology uses food production residues to produce materials that are compostable under natural composting conditions and provides a marketable product from agricultural residues such as starch or brewery residues as a raw material for home compostable, harmless for the environment and humans, enabling the society to get rid of the plastic materials that lead to serious environmental, marine pollution and lower carbon emissions.
SwissDeCode Sàrl, founded in 2016 and based in Renens, Switzerland, specializes in providing rapid on-site DNA testing solutions for the food industry. The company focuses on ensuring food safety and authenticity by offering plug-and-play testing services that allow food manufacturers to receive quality and safety certifications within the same work shift. This capability enables immediate decision-making regarding food authenticity and compliance, helping to transform potential contamination risks into sustainable opportunities for producers. By validating the integrity of the food supply chain, SwissDeCode supports food manufacturers in delivering safe and reliable products to consumers.
Arborea Ltd. is a biochemical technology company based in London, UK, that focuses on developing sustainable bio-based products using its proprietary BioSolar Leaf technology. Founded in 2015, Arborea's innovative system cultivates microscopic plants, facilitating the production of healthy food ingredients such as antioxidants and functional proteins while also sequestering carbon dioxide and generating breathable oxygen. This technology not only supports urban and industrial applications but also enhances air quality and reduces energy consumption for climate control in buildings. By enabling large-scale algae biomass production, Arborea aims to provide a cost-effective and scalable solution for the sustainable food industry, aligning with environmental goals and promoting healthier food options.
N2 Applied is a Norwegian technology company focused on innovative solutions for nitrogen fertilizer production directly on farms. Established in 2010 and headquartered in Oslo, the company has developed a method that allows livestock farmers to convert liquid organic substrates, such as manure and biogas digestate, into fertilizer by extracting nitrogen from the air. This process not only enhances the nitrogen content of the substrate but also mitigates ammonia loss and lowers greenhouse gas emissions. N2 Applied's technology promotes resource efficiency and cost savings for farmers by facilitating local fertilizer production, thus eliminating the need for long supply chains and reliance on fossil-based chemical fertilizers. The company's scalable system contributes to a circular farming model, offering additional benefits such as reductions in methane and ammonia emissions, as well as minimizing odors. N2 Applied operates a test center in Norway and has branches in the Netherlands and the UK, positioning itself within the realms of livestock farming, organic agriculture, and sustainable practices.
enGenome is a bioinformatics company provides accurate omics-based reports to physicians, thus improving diagnosis and treatment processes for patients. Their products and services helps to improve the diagnosis of genetic diseases and patients therapies by producing accurate genetic reports.
Producer of food ingredients intended to provide upcycled ingredients for nutrition. The company's fermentation platform transforms wasted fruit and vegetable by-products into low-carb flour with improved nutritional value and functionality, enabling clients to get flour that is high in protein and dietary fiber, while being low in starch, sugars, and fats.
Palobiofarma S.L. is a biotechnology company based in Barcelona, Spain, with an additional facility in Navarra. Founded in 2005, the company specializes in the discovery and development of new drugs that target adenosine receptors, with a focus on treating advanced prostate cancer. By leveraging medicinal chemistry and in vitro pharmacology, Palobiofarma aims to be the first European company to market a selective adenosine receptor modulator, addressing significant medical needs through innovative therapeutic approaches.
Palobiofarma S.L. is a biotechnology company based in Barcelona, Spain, with an additional facility in Navarra. Founded in 2005, the company specializes in the discovery and development of new drugs that target adenosine receptors, with a focus on treating advanced prostate cancer. By leveraging medicinal chemistry and in vitro pharmacology, Palobiofarma aims to be the first European company to market a selective adenosine receptor modulator, addressing significant medical needs through innovative therapeutic approaches.
Sequentia Biotech, founded in 2013 by Walter Sanseverino and Riccardo Aiese Cigliano, is a bioinformatics company based at the UAB Research Park. The company specializes in transforming genomic data into actionable insights for various sectors, including academic research, plant and animal breeding, and biomedicine. Sequentia collaborates with over 30 public and private research centers, universities, and companies, participating in more than 160 research and development projects. The company offers a range of services, including cloud software, custom software solutions, and bioinformatics consulting, aimed at advancing healthcare, agriculture, and environmental sciences. Sequentia Biotech also maintains two open-source biodata banks and has developed an award-winning research initiative called Tricopharming. The founders have contributed significantly to the field, with over 40 scientific publications in prestigious journals.
Sequentia Biotech, founded in 2013 by Walter Sanseverino and Riccardo Aiese Cigliano, is a bioinformatics company based at the UAB Research Park. The company specializes in transforming genomic data into actionable insights for various sectors, including academic research, plant and animal breeding, and biomedicine. Sequentia collaborates with over 30 public and private research centers, universities, and companies, participating in more than 160 research and development projects. The company offers a range of services, including cloud software, custom software solutions, and bioinformatics consulting, aimed at advancing healthcare, agriculture, and environmental sciences. Sequentia Biotech also maintains two open-source biodata banks and has developed an award-winning research initiative called Tricopharming. The founders have contributed significantly to the field, with over 40 scientific publications in prestigious journals.
FibriTech specializes in the development of advanced technologies for the production of 3D fiber network materials, which have a variety of applications across multiple industries. The company provides innovative solutions in areas such as agritech, packaging, filtration, insulation, and biocomposites. FibriTech's products offer a sustainable alternative to conventional materials like Styrofoam and various foamed plastics, delivering lightweight yet strong biomaterials that are both functional and environmentally friendly. By focusing on the creation of spatially shapable materials, FibriTech aims to address the challenges posed by traditional materials while promoting sustainability in manufacturing processes.
Genome Biologics are leaders in therapeutic target discovery and RNA-targeted therapies in cardiovascular and cardiometabolic disease. Our technology platforms seamlessly integrate synergistically to accelerate development of RNAi therapies to treat illnesses where no other treatments have proven effective or ever existed.
Epigene Labs SAS, founded in 2019 and headquartered in Paris, France, with an additional office in Boston, Massachusetts, develops a biotechnology platform that harnesses advanced artificial intelligence to transform genomic data into actionable insights for precision oncology. The platform addresses the challenges of aggregating, analyzing, and visualizing extensive genomic datasets, which are crucial for advancing precision oncology. By integrating proprietary data from partners with publicly available information, Epigene Labs provides medical researchers with user-friendly analytics and insights that facilitate drug development and research in cancer treatment. The company focuses on forming value-based partnerships with leading cancer centers and prominent biotech firms to enhance the efficacy of oncology solutions.
RemedyBio is an immunology-focused discovery and development company based in Dublin, Ireland. It has pioneered a new approach to understanding the immune system and the discovery of new therapies.
AgroSustain SA is a Swiss company founded in 2018, specializing in the development of natural and organic solutions to combat fungal pathogens affecting key agricultural crops during the post-harvest phase. The company utilizes plant extracts to create coatings and treatments that effectively inhibit the growth of harmful fungi, such as botrytis cinerea and fusarium oxysporum. By focusing on sustainable practices, AgroSustain aims to extend the shelf life and quality of fruits and vegetables, thereby reducing food waste and minimizing plastic consumption in the agricultural sector. Their innovative approach not only aids farmers in preserving their produce but also contributes to more environmentally friendly agricultural practices.
Xenothera SAS is a biotechnology company based in Nantes, France, focused on advancing immunological treatments through its innovative platform. Established in 2014, the company specializes in developing therapeutic solutions targeting various medical areas, including immunomodulation and infectious diseases. Its approach leverages proprietary Glyco-Humanized Antibodies and integrates expertise in animal genetics and immunology to create a new generation of hyperimmune polyclonal sera. By renovating passive immunotherapy, Xenothera aims to address unmet medical needs and facilitate the rapid development of new immunological therapies. The company's comprehensive platform allows for streamlined processes, from selecting immunogens to purifying immunoglobulins, ultimately aiming for expedited market authorization.
Xenothera SAS is a biotechnology company based in Nantes, France, focused on advancing immunological treatments through its innovative platform. Established in 2014, the company specializes in developing therapeutic solutions targeting various medical areas, including immunomodulation and infectious diseases. Its approach leverages proprietary Glyco-Humanized Antibodies and integrates expertise in animal genetics and immunology to create a new generation of hyperimmune polyclonal sera. By renovating passive immunotherapy, Xenothera aims to address unmet medical needs and facilitate the rapid development of new immunological therapies. The company's comprehensive platform allows for streamlined processes, from selecting immunogens to purifying immunoglobulins, ultimately aiming for expedited market authorization.
Lactips is a French company founded in 2014 and headquartered in Lyon. It specializes in manufacturing biodegradable and water-soluble thermoplastic pellets derived from milk protein. The company employs a proprietary industrial process to produce these pellets quickly and in high volumes, making them suitable for various applications, including thermoforming and films. Lactips aims to offer its industrial clients innovative and sustainable alternatives to traditional oil-based plastics, aligning with its commitment to environmental sustainability and efficiency. By providing these disruptive solutions, Lactips supports its clients in accessing new markets while promoting a cleaner and more sustainable approach to plastic usage.
Risutec provides solutions for improving forest and agricultural planting and maintenance.
Qubit Pharmaceuticals, incorporated in 2020 and based in Paris, France, develops innovative technology aimed at enhancing pharmaceutical drug discovery. The company offers a drug discovery simulation platform that reduces the cost and duration of preclinical drug development. Utilizing proprietary force field models and molecular dynamics calculations, Qubit's platform conducts virtual screening and visualization to identify promising drug candidates. This approach leverages quantum physics to support biopharmaceutical companies in accelerating their research and development efforts.
PROSION is a pharmaceutical & drug discovery start-up company.
Developer of microbiome analysis technology designed to monitor the microbiome status and function and quantify its impact on all aspects of human life. The company's technology simplifies, accelerates, and democratizes microbiome analysis to precisely measure the composition and dynamics of the microbiome by uncovering its role in human health and the environment, enabling researchers to access genetic analysis devices to analyze the full genetic makeup of microbiomes.
Developer of microbiome analysis technology designed to monitor the microbiome status and function and quantify its impact on all aspects of human life. The company's technology simplifies, accelerates, and democratizes microbiome analysis to precisely measure the composition and dynamics of the microbiome by uncovering its role in human health and the environment, enabling researchers to access genetic analysis devices to analyze the full genetic makeup of microbiomes.
Smart4Diagnostics GmbH is a Munich-based company founded in 2018 that specializes in the production of digital data fingerprints for human blood samples. The company has developed a device designed for precise blood sample measurement, aiming to enhance the accuracy and reliability of diagnostic processes. By focusing on innovative solutions in the medical technology sector, Smart4Diagnostics contributes to advancements in healthcare diagnostics.
AgroSustain SA is a Swiss company founded in 2018, specializing in the development of natural and organic solutions to combat fungal pathogens affecting key agricultural crops during the post-harvest phase. The company utilizes plant extracts to create coatings and treatments that effectively inhibit the growth of harmful fungi, such as botrytis cinerea and fusarium oxysporum. By focusing on sustainable practices, AgroSustain aims to extend the shelf life and quality of fruits and vegetables, thereby reducing food waste and minimizing plastic consumption in the agricultural sector. Their innovative approach not only aids farmers in preserving their produce but also contributes to more environmentally friendly agricultural practices.
NIL Technology ApS is a nanotechnology company based in Kongens Lyngby, Denmark, with a branch in Gothenburg, Sweden. Established in 2006, the company specializes in the optical design, prototyping, and mass production of optical components. NIL Technology offers nanostructured masters for various replication technologies, such as nanoimprint, UV-replication, hot embossing, roll printing, and injection molding. Its product range includes diffractive optical elements, microlens arrays, beam splitters, optical diffusers, and waveguides for augmented and mixed reality applications. The company's solutions cater to diverse sectors, including biotechnology, renewable energy, consumer product packaging, and advanced imaging technologies. By focusing on optical applications for sensors, 3D displays, and smartphones, NIL Technology aims to enable innovative optical solutions for a variety of high-tech industries.
Omnix Medical is dedicated to the development and commercialization of highly effective antibiotic agents against resistant pathogenic bacterial strains. Omnix is addressing an enormous and rapidly growing threat to public health, represented by millions worldwide, who suffer from infections associated with resistant bacteria. Omnix’s technology will tilt the odds in the battle against resistant bacteria and improve the lives of many people worldwide.
SepTec is developing and commercializing a revolutionary sample-to-answer sepsis diagnostic device that can rapidly detect pathogens in whole blood.
Cellugy is a biotechnology startup focused on creating sustainable alternatives to single-use plastics through the production of 100% natural bio-cellulose. Utilizing a fermentation platform, the company harnesses renewable resources instead of fossil fuels to develop high-quality cellulose that competes effectively in terms of economics and environmental impact. Cellugy's innovative approach allows for the production of various grades and qualities of cellulose, making it applicable across multiple industries, including personal care, packaging, textiles, and food. By offering a more sustainable solution, Cellugy aims to significantly reduce the environmental footprint associated with traditional materials.
Deep Branch Biotechnology Ltd., founded in 2018 and based in Nottingham, United Kingdom, with additional offices in the Netherlands, specializes in carbon recycling services. The company has developed scalable technology that converts carbon dioxide from industrial waste gas into clean, nutritious, and sustainable single-cell protein. This innovative process not only helps to reduce the carbon footprint of polluting industries but also offers sustainable alternatives to traditional feed sources such as soy and fishmeal. By transforming emissions into valuable protein, Deep Branch Biotechnology aims to contribute to a more sustainable future in the feed industry.
Separative is a startup bringing a break in the purification of molecules in organic chemistry and peptides.
Omnix Medical is dedicated to the development and commercialization of highly effective antibiotic agents against resistant pathogenic bacterial strains. Omnix is addressing an enormous and rapidly growing threat to public health, represented by millions worldwide, who suffer from infections associated with resistant bacteria. Omnix’s technology will tilt the odds in the battle against resistant bacteria and improve the lives of many people worldwide.
SepTec is developing and commercializing a revolutionary sample-to-answer sepsis diagnostic device that can rapidly detect pathogens in whole blood.
LIVIN farms is a technology company in the alternative protein sector. It empowers everyone to start a food revolution out of their kitchen.
SwissDeCode Sàrl, founded in 2016 and based in Renens, Switzerland, specializes in providing rapid on-site DNA testing solutions for the food industry. The company focuses on ensuring food safety and authenticity by offering plug-and-play testing services that allow food manufacturers to receive quality and safety certifications within the same work shift. This capability enables immediate decision-making regarding food authenticity and compliance, helping to transform potential contamination risks into sustainable opportunities for producers. By validating the integrity of the food supply chain, SwissDeCode supports food manufacturers in delivering safe and reliable products to consumers.
Faron is a clinical stage biopharmaceutical company developing novel treatments for medical conditions with significant unmet needs. The Company currently has a pipeline focusing on acute organ traumas, vascular damage and cancer immunotherapy.
Ilya Pharma AB is a biotechnology company based in Uppsala, Sweden, that specializes in developing biological drugs aimed at treating wounds in skin and mucosa. Founded in 2016, the company focuses on addressing both acute and chronic wounds, particularly those affecting individuals with diabetes. Ilya Pharma employs a unique approach by genetically modifying lactic acid bacteria, commonly found in yogurt, to produce substances that enhance the healing process of skin injuries. Their innovative drug delivery system utilizes these bacteria as vectors to administer biological drugs directly at the wound site or within the gastrointestinal tract, facilitating accelerated healing in a cost-effective manner. The company’s research and development efforts are rooted in extensive scientific studies conducted at Uppsala University and the Swedish University of Agriculture.
FluoGuide A/S is a Copenhagen-based company that focuses on developing surgical solutions to enhance cancer treatment outcomes. Founded in 2018, the company is known for its product FG001, which utilizes a fluorophore that specifically binds to cancer cells expressing the urokinase receptor. By employing intelligent targeting techniques, FluoGuide aims to improve surgical precision, thereby reducing patient suffering and increasing the chances of successful treatment. Additionally, the company seeks to lower healthcare costs associated with cancer surgeries.
RemedyBio is an immunology-focused discovery and development company based in Dublin, Ireland. It has pioneered a new approach to understanding the immune system and the discovery of new therapies.
Nanogence SA manufactures novel material solutions for the construction sector. The company develops synthetic tailor-made novel material in a B2B framework in application sectors such as construction, pharmaceutical and mobility. Nanogence SA was founded in 2017 and is based in Renens, Switzerland.
TomaPaint specializes in the production of bio-resins derived from by-products of industrial tomato processing. The company focuses on creating an organic-based lacquer designed for use in food packaging, particularly for the internal coating of food cans. This innovative lacquer serves as an ecological alternative to traditional synthetic petrochemical-based resins, aiming to transform the metal food packaging industry. By utilizing waste recycling and cutin extraction, TomaPaint contributes to significant environmental and health benefits, enabling industries to lower carbon emissions and minimize the use of hazardous chemicals.
Ability Pharmaceuticals, S.L. is a clinical stage biopharmaceutical company based in Barcelona, Spain, dedicated to the discovery and development of human therapeutics for cancer and other unmet medical needs. The company specializes in creating Lipid Analogue Therapeutics, a novel class of small molecules designed to be administered orally. Its primary focus is on developing treatments for lung, pancreatic, and gynecological cancers. The development pipeline includes ABTL0812, which targets the Akt/mTOR signaling pathways, and ABTL0815, currently in preclinical characterization. Ability Pharmaceuticals develops its drug candidates up to clinical proof of concept before out-licensing them to pharmaceutical companies for further development. Founded in 2009, the company was formerly known as AB Therapeutics, S.L. and changed its name in September 2012.
ADmit Therapeutics, S.L. is a biotechnology company based in Begues, Spain, dedicated to the development of diagnostic tests for the early detection of Alzheimer’s disease. Founded in 2017, the company utilizes epigenetic analysis of blood samples to identify a series of mitochondrial biomarkers that are not related to traditional indicators such as ß-amyloid or tau proteins. By analyzing a large number of methylcytosines in mitochondrial DNA through next-generation sequencing, ADmit Therapeutics provides a novel and accessible method for medical practitioners to detect early-stage Alzheimer’s disease. Their innovative approach primarily serves pharmaceutical companies, aiming to enhance diagnostic capabilities in the field of neurodegenerative diseases.
SwissDeCode Sàrl, founded in 2016 and based in Renens, Switzerland, specializes in providing rapid on-site DNA testing solutions for the food industry. The company focuses on ensuring food safety and authenticity by offering plug-and-play testing services that allow food manufacturers to receive quality and safety certifications within the same work shift. This capability enables immediate decision-making regarding food authenticity and compliance, helping to transform potential contamination risks into sustainable opportunities for producers. By validating the integrity of the food supply chain, SwissDeCode supports food manufacturers in delivering safe and reliable products to consumers.
Xenothera SAS is a biotechnology company based in Nantes, France, focused on advancing immunological treatments through its innovative platform. Established in 2014, the company specializes in developing therapeutic solutions targeting various medical areas, including immunomodulation and infectious diseases. Its approach leverages proprietary Glyco-Humanized Antibodies and integrates expertise in animal genetics and immunology to create a new generation of hyperimmune polyclonal sera. By renovating passive immunotherapy, Xenothera aims to address unmet medical needs and facilitate the rapid development of new immunological therapies. The company's comprehensive platform allows for streamlined processes, from selecting immunogens to purifying immunoglobulins, ultimately aiming for expedited market authorization.
SOMAprobes S.L. develops healthcare technology for magnetic resonance imaging detection of bacterial pathogens at the onset of infectious disease. The company was incorporated in 2014 and is based in Donostia, Spain.
Betalin Therapeutics is a privately-held company focused on developing a cell therapy solution for insulin-dependent diabetes through its Engineered Micro-Pancreas (EMP) technology. The EMP combines harvested pancreatic islets, known as Islets of Langerhans, with a proprietary biological micro-environment designed to support these cells. After achieving promising in-vitro results and preliminary in-vivo outcomes, the company is working to further optimize its therapy in animal models. Betalin Therapeutics aims to complete the submission of its Investigational New Drug application to the FDA and advance to clinical trials, with the goal of providing an alternative to traditional insulin therapy and eliminating the need for insulin injections and glucose testing in diabetes patients.
Faron is a clinical stage biopharmaceutical company developing novel treatments for medical conditions with significant unmet needs. The Company currently has a pipeline focusing on acute organ traumas, vascular damage and cancer immunotherapy.
Biome Makers Inc. is a biotechnology company based in San Francisco, California, founded in 2015. The company specializes in understanding and identifying microbiomes, particularly in the context of agriculture. By utilizing DNA sequencing technologies and proprietary Intelligent Computing systems, Biome Makers provides detailed, crop-specific insights and recommendations to enhance agricultural production and product quality. Their technology enables growers and manufacturers to analyze soil ecosystems effectively, offering data-driven insights that facilitate improved decision-making in farming practices.
Ability Pharmaceuticals, S.L. is a clinical stage biopharmaceutical company based in Barcelona, Spain, dedicated to the discovery and development of human therapeutics for cancer and other unmet medical needs. The company specializes in creating Lipid Analogue Therapeutics, a novel class of small molecules designed to be administered orally. Its primary focus is on developing treatments for lung, pancreatic, and gynecological cancers. The development pipeline includes ABTL0812, which targets the Akt/mTOR signaling pathways, and ABTL0815, currently in preclinical characterization. Ability Pharmaceuticals develops its drug candidates up to clinical proof of concept before out-licensing them to pharmaceutical companies for further development. Founded in 2009, the company was formerly known as AB Therapeutics, S.L. and changed its name in September 2012.
S-Biomedic is a Belgian biotech company specializing in live probiotic cosmetics designed to improve skin health. The company focuses on the skin microbiome, a complex ecosystem of beneficial and harmful bacteria that plays a crucial role in skin conditions such as acne, eczema, rosacea, and aging. S-Biomedic employs advanced modulation-based technology to selectively harness beneficial bacteria, creating products that promote the rebalancing of the skin microbiome. By utilizing the latest advancements in microbiology and dermatology, their offerings aim to restore healthy skin and address various dermatological concerns. Through this innovative approach, S-Biomedic provides therapeutic solutions in both the dermatology and cosmetic sectors, enhancing the overall health and beauty of the skin.
Aiforia Technologies was founded as a spin-off company from the Finnish Institute for Molecular Medicine (FIMM) at the University of Helsinki in 2013 by researchers and pioneers in the field of cloud-based microscopy and pathology and experienced life science entrepreneurs. The Aiforia® Platform brings together deep learning AI and high-performance cloud computing. Aiforia assists with the increased demand for image-based diagnostics by providing efficient and scalable solutions – enabling new discoveries and clinical support with highly accurate and consistent data. Aiforia is technologically driven establishment and keeps the capability of being image agnostic thus extending its solutions to multiple fields.
They at Biomendex develop and manufacture adaptable synthetic bone substitute materials for bone regeneration. Their invention, Adaptos™, is the first bioactive bone graft substitute that surgeons can cut, shape or squeeze into place. It is the only bone graft substitute that mimics bone by being resilient and bioactive.
Antofénol is a post-harvest biocontrol company focused on reducing losses in agricultural produce, particularly in viticulture. The company specializes in the ecological eco-extraction of plant matter, utilizing innovative techniques such as microwaves, ultrasonics, vacuum, and mixing to develop tailored chemical compositions. Antofénol offers services that include eco-extraction, anti-fungal testing, and biochemical characterization, allowing harvesters to effectively protect fruits and vegetables from fungal and mold infestations. Through its approach, Antofénol aims to valorize viticultural waste while promoting sustainable agricultural practices.
Medicortex Finland is focused on developing a non-invasive, point-of-care diagnostic test for Traumatic Brain Injury (TBI) and concussions. Traditional diagnostic methods, such as CT and MRI scans, struggle to accurately diagnose mild TBIs. To address this, Medicortex is identifying brain injury biomarkers that can be detected from urine and saliva, with plans to incorporate these biomarkers into a hand-held diagnostic kit that provides rapid and reliable results without the need for medical professionals' interpretation. The company aims to collaborate with larger diagnostic firms for manufacturing and distribution. Its target customers include hospitals, emergency rooms, paramedics, military personnel, sports teams, pharmaceutical companies, and insurance providers. Medicortex has achieved significant milestones, including reaching Phase II clinical studies for its biomarker and receiving grant funding from the US Department of Defense, the European Union, and the Finnish Government.
Created in July 2014, Aenitis Technologies is a French start-up resulting from the work of Mauricio HOYOS and Jean-Luc AIDER, both CNRS researchers at the PMMH Laboratory (Physics and Mechanics of Heterogeneous Media at the ESPCI ParisTech, a research engineer’s school in Paris. The company focuses on medical devices’ area, where their breakthrough technologies are highly promising. Aenitis Technologies is developing innovative separation, manipulation and filtration of biological elements solutions, based on acoustophoresis technologies. The company first focuses on technological solutions that will revolutionize current practices in Public Health. Aenitis Technologies aims to become a world leader in filtering / separating solutions by acoustophoresis.